James L. Riley

California University of Pennsylvania — United States

Immunology and Microbiology · Life Sciences

76h-index26.6kcitations276works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(145), CAR-T cell therapy research(98), T-cell and B-cell Immunology(87), Immunotherapy and Immune Responses(65), HIV Research and Treatment(39)

Publications274 total

Supplementary Figure 7 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 4 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 1 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 2 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 5 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 3 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Table 1 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 6 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease
Blood·2025Open Access
557 Evaluation of huCART19-IL18 manufactured using Synecta™ CDNP technology to improve CAR-T yield and consistency in cohort D of an ongoing phase I study (NCT04684563)
Regular and Young Investigator Award Abstracts·2025Open Access
p:Hishing for T cells: Using ‘chimeric antigen-presenting’ (CAP) T cells to target and eliminate antigen-specific T cell populations 4027
The Journal of Immunology·2025Open Access
Cell-derived nanoparticles generated from cell-based artificial antigen presenting cells allow for the robust and rapid manufacturing of patient T cells 9064
The Journal of Immunology·2025Open Access
CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy
Nature Biomedical Engineering·2025· 1 cited
<i>Cryptosporidium</i> aspartyl protease 2 is required for host cell egress of merozoites and male gametes
Molecular Biology of the Cell·2025· 1 citedOpen Access
Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy
Molecular Therapy·2025· 1 citedOpen Access
Using Donor-Specific CAR Regulatory T-Cells to Promote Heart Allograft Tolerance in NHPs
American Journal of Transplantation·2025Open Access
Data from CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target
2025Open Access
Supplemental Figure 1 from CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target
2025Open Access
Supplementary Data from CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target
2025Open Access
Supplemental Figure 2 from CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target
2025Open Access
page 1 of 14Next →

Frequent Co-authors

Carl H. June(32), Richard G. Carroll(10), Bruce L. Levine(8), Bruce R. Blazar(8), Megan M. Suhoski(6), Angel Varela‐Rohena(6), Tatiana N. Golovina(6), Carmine Carpenito(5), Gabriela Plesa(5), Keli L. Hippen(5), Richard V. Parry(4), Michael C. Milone(4), Jeffrey S. Miller(4), Craig B. Thompson(3), Gwenn Danet-Desnoyers(3), Jianbin Wang(3), Philip D. Gregory(3), Michael C. Holmes(3), Steven Μ. Albelda(3), John Scholler(3)